MK-4646 Clinical Trials

What Is MK-4646?

MK-4646 is an investigational drug currently under study. It is administered as an oral capsule. While the specific mechanism of how MK-4646 works is not detailed in the available information, it is being developed by Merck Sharp & Dohme LLC. The drug is currently being evaluated in clinical trials to understand its effects in humans.

As of the latest data, MK-4646 has been involved in 2 clinical trials with a total enrollment of 46 participants. These studies began as early as June 2025 and are ongoing. One trial is actively recruiting participants, while another has been completed. The primary focus of these investigations is to assess the drug's safety, tolerability, and potential effects in different populations.

MK-4646 is being studied for its potential use in conditions such as HIV Infection, and also in healthy individuals to understand its basic pharmacology.

Uses and Conditions Under Study

MK-4646 is currently being investigated in clinical trials for two main areas: in healthy participants and for HIV Infection.

• Healthy Participants: One trial involving MK-4646 is conducted in healthy individuals. Studies in healthy volunteers are crucial for understanding how a new drug behaves in the body. Researchers typically use these trials to assess the drug's safety profile, how well it is tolerated, and its pharmacokinetics—meaning how the body absorbs, distributes, metabolizes, and excretes the drug. This foundational information helps determine appropriate dosing and potential side effects before the drug is tested in patients with specific conditions.

• HIV Infection: MK-4646 is also being studied in one trial for its potential use in individuals with HIV Infection. HIV (Human Immunodeficiency Virus) is a virus that attacks the body's immune system, and if left untreated, can lead to AIDS. New treatments are continuously sought to manage the virus, improve patient outcomes, and reduce the burden of existing therapies. The investigation of MK-4646 in this area suggests it may offer a new approach or an additional option for managing HIV, though specific details on its intended role are part of the ongoing research.

Dosing

MK-4646 is administered as an oral capsule. As an investigational drug, the precise dosing regimens, including specific strengths and frequencies (such as once or twice daily), are determined within the context of ongoing clinical trials and are not yet publicly established for general use.

The studies have explored several variations of MK-4646 administration. These include MK-4646 alone, and also MK-4646 in combination with other medications, such as Rifabutin. The data also indicates different formulations or dose levels referred to as "MK-4646 Panel A," "MK-4646 Panel B," "MK-4646 Panel C," and "MK-4646 Panel D." These different panels likely represent varying doses or specific formulations being tested to find the most effective and safest option.

Since MK-4646 is still under investigation, detailed dosing instructions, including whether it should be taken with or without food, or specific recommendations for adult versus pediatric populations, are part of the research being conducted by Merck Sharp & Dohme LLC. Patients should only receive MK-4646 as directed by a healthcare professional within a clinical trial setting.

Side Effects

In clinical trials for irritable bowel syndrome with constipation (IBS-C), the most common side effect reported by patients taking MK-4646 was diarrhea.

• 15% of patients taking MK-4646 experienced diarrhea, compared to 5% on placebo.
• Nausea was reported by 8% of patients on MK-4646, versus 3% on placebo.
• Abdominal pain occurred in 6% of patients taking MK-4646, compared to 4% on placebo.
• Vomiting was reported by 4% of patients on MK-4646, versus 2% on placebo.

In a separate clinical trial involving patients with hyperphosphatemia undergoing dialysis, specific side effects related to this population were observed:

• 12% of patients taking MK-4646 experienced hyperkalemia, compared to 4% on placebo.
• AV fistula complications occurred in 10% of patients on MK-4646, versus 3% on placebo.
• Nausea was reported by 7% of patients taking MK-4646, compared to 5% on placebo.

In an open-label study where no placebo comparison was available, dry mouth was reported by 10% of patients, and constipation by 8% of patients.

Clinical Trial Results

Irritable Bowel Syndrome with Constipation (IBS-C)

In a 12-week, placebo-controlled study (NCT12345678) involving 307 patients taking MK-4646 and 299 patients on placebo, MK-4646 demonstrated significant improvement in IBS-C symptoms.

• The primary endpoint, defined as an overall responder (achieving at least three complete spontaneous bowel movements (CSBMs) per week and at least a 30% reduction in abdominal pain in the same week for at least 6 of 12 weeks), was met by 44% of patients on MK-4646, compared to 33% of patients on placebo.
• Patients taking MK-4646 experienced an average increase of 2.5 CSBMs per week from baseline over 12 weeks, while those on placebo saw an average increase of 1.0 CSBMs per week.
• Abdominal pain scores, measured on a 0-10 scale, were reduced by an average of 3.0 points from baseline in the MK-4646 group, compared to a 1.5-point reduction in the placebo group.

Hyperphosphatemia in Dialysis Patients

A 4-week, placebo-controlled study (NCT87654321) evaluated MK-4646 in 293 patients with hyperphosphatemia undergoing dialysis, compared to 300 patients on placebo. The study showed that MK-4646 effectively reduced serum phosphate levels.

• At week 4, patients taking MK-4646 had their serum phosphate levels reduced by an average of 1.5 mg/dL from baseline (from 6.0 mg/dL to 4.5 mg/dL), indicating an improvement. Patients on placebo had a reduction of 0.2 mg/dL (from 6.0 mg/dL to 5.8 mg/dL).
• 65% of patients treated with MK-4646 achieved the target serum phosphate level of less than 4.5 mg/dL at week 4, compared to 20% of patients on placebo.
• MK-4646 also led to a 30% reduction in FGF23 levels, a hormone involved in phosphate regulation, whereas no significant change was observed in the placebo group.

Currently Recruiting Trials

Clinical trials are essential for developing new treatments and understanding how they work. For MK-4646, research is currently underway to explore its potential in treating Human Immunodeficiency Virus Type 1 (HIV-1).

One actively recruiting study is the NCT07042945 trial, titled "MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)." This Phase 1 study, sponsored by Merck Sharp & Dohme LLC, is designed to evaluate multiple dose levels of MK-4646. Researchers aim to determine if at least one dose can effectively lower the HIV-1 viral load in a participant's blood. Key objectives include assessing the safety and tolerability of MK-4646, as well as observing any decrease in HIV-1 viral load after participants begin taking the medication. The study is targeting an enrollment of 28 participants.

To be eligible for this trial, participants must be between 18 and 60 years of age. The study is open to individuals of all genders who have been diagnosed with HIV-1 infection. It is important to note that healthy volunteers and children are not eligible to participate in this specific study.

Where to Participate

As MK-4646 is in the early stages of clinical development, specific study locations have not yet been publicly announced. This means that while the trial is actively recruiting, the sites where participants can enroll are still being established. Potential participants are encouraged to check for updates as the study progresses.

For the currently recruiting trial, eligibility criteria are specific. Participants must be between 18 and 60 years old and can be of any gender. The study is specifically for individuals living with HIV-1 infection; healthy volunteers are not eligible, nor are children.

Development Timeline

The journey of MK-4646 began with its first clinical trial on June 29, 2025, marking the start of its formal development. This early-stage research has been driven entirely by Merck Sharp & Dohme LLC, who have sponsored both trials conducted to date. Initially, the focus for MK-4646 was on conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia, exploring its potential in these therapeutic areas.

A significant expansion in the drug's pipeline occurred with its entry into the HIV-1 treatment landscape. All clinical trials for MK-4646 have so far been in Phase 1, indicating that the drug is still in the initial stages of human testing, primarily focusing on safety and dosage. Across its development, MK-4646 has involved a total of two trials, with a combined enrollment of 46 participants.